Prospect Of Predictive Gene Test Grips Developers Of Hepatitis C Drugs
Executive Summary
The discovery of a gene marker that foretells the effectiveness of current standard-of-care therapy in hepatitis C offers a new tool for drug development and a potential guide for clinicians
You may also be interested in...
Hep C Cost-Effectiveness Study Supports Limiting Incivek Use
Study presented at AASLD provides evidence of the potential value of genotyping patients prior to treatment with new protease inhibitors; Medco ready to start testing program.
Vertex, Merck Face Education Challenge With Complex Hep C Regimens
With two direct acting antivirals now pending at FDA, the hepatitis C community is excited about adding efficacious new drugs to standard of care. But the regimens aren't as simple as that sounds; once the therapies are approved, the sponsors will have a considerable education effort on their hands, as physicians and patients work their way through the new HCV treatment calculus.
Vertex, Merck Face Education Challenge With Complex Hep C Regimens
With two direct acting antivirals now pending at FDA, the hepatitis C community is excited about adding efficacious new drugs to standard of care. But the regimens aren't as simple as that sounds; once the therapies are approved, the sponsors will have a considerable education effort on their hands, as physicians and patients work their way through the new HCV treatment calculus.